Hormonal
Sleep duration has a non-linear (L-shaped or U-shaped) relationship with MACE subtypes, with optimal benefits for heart failure but potential risks for myocardial infarction and stroke at longer durations.
While getting enough sleep (8-9.5 hours) is generally beneficial for heart health, be aware that the relationship between sleep duration and specific heart conditions varies. For heart failure, more sleep is linearly beneficial. For heart attacks and strokes, very long sleep durations might not offer additional benefits and could potentially be linked to other risks. Aim for the 8-9.5 hour range as a general guideline.
Sleep displayed an L-shaped relationship for MACE, MI, and stroke, while a linear dose-response relationship was observed for HF. ... Longer sleep for MI and stroke may be partially explained or exacerbate circadian dysregulation, which can increase pro-thrombotic triggering processes.
Why this rating
Large prospective cohort with objective measures.
Source
Clinically meaningful combined improvements of sleep, physical activity, and nutrition (SPAN) in relation to major adverse cardiovascular events
Nicholas A. Koemel et al. · medRxiv · 2025
DOI 10.1101/2025.09.10.25335537
More from this paper
- Modest combined improvements in sleep (11 min/day), physical activity (4.5 min/day MVPA), and nutrition (3 DQS points) are associated with a clinically meaningful 10% reduction in major adverse cardiovascular events (MACE).Good
- Optimal combined SPAN behaviors (high sleep 8.0-9.4h, high MVPA 42-104min, high diet quality 57.5-72.5) are associated with a 57% lower risk of MACE compared to the lowest tertile of all behaviors.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →